24
Isaac “Zak” Kohane, MD, PhD From Bedside to Bench and Back

From Bedside to Bench and Back

  • Upload
    crwys

  • View
    43

  • Download
    0

Embed Size (px)

DESCRIPTION

From Bedside to Bench and Back. Isaac “ Zak ” Kohane, MD, PhD. First signal: 1 year after Celecoxib 8 months after Rofecoxib. Oral Hypoglycemic Agents. Without strong priors. Major Modes of E HR D riven G enomic R esearch (EDGR). EHR. EHR. EDGR Advantages. Timeliness - PowerPoint PPT Presentation

Citation preview

Page 1: From Bedside to Bench  and Back

Isaac “Zak” Kohane, MD, PhD

From Bedside to Bench and Back

Page 2: From Bedside to Bench  and Back

First signal:• 1 year after

Celecoxib • 8 months

after Rofecoxib

Page 3: From Bedside to Bench  and Back

Oral Hypoglycemic Agents

Page 4: From Bedside to Bench  and Back

Without strong priors

Page 5: From Bedside to Bench  and Back

Major Modes of EHR Driven Genomic Research (EDGR)

EHR

EHR

Page 6: From Bedside to Bench  and Back

EDGR Advantages

• Timeliness• Clinical Relevance• Underserved populations• Controls• Co-morbidity recognition (e.g. PheWAS)

Page 7: From Bedside to Bench  and Back

Accrual Rates

Murphy et al Genome Research, 2009

Page 8: From Bedside to Bench  and Back

Costs

Murphy et al Genome Research, 2009

Page 9: From Bedside to Bench  and Back

Kurreeman, AJHG 2011But it works…

Page 10: From Bedside to Bench  and Back

Kurreeman, AJHG 2011

Page 11: From Bedside to Bench  and Back

Timeline

Page 12: From Bedside to Bench  and Back

EDGR Challenges

• Consent (None/Opt-in/Opt-Out)• Cost of EHRs• Quality of EHR data• Lack of Family History codification• Lack of EHR standardization• Cultural gulf between clinical informatics

and bioinformatics.– Translational Bioinformatics

Page 13: From Bedside to Bench  and Back

Application to a common pediatric disease

• With an understudied epidemiology

Page 14: From Bedside to Bench  and Back

Aggregating across 4 hospitals, 3 i2b2 instances

Page 15: From Bedside to Bench  and Back
Page 16: From Bedside to Bench  and Back

Co-morbidities in autism vs. hospital population

Page 17: From Bedside to Bench  and Back

2012

SHRINE conf 6/29

Page 18: From Bedside to Bench  and Back

Thank you

Page 19: From Bedside to Bench  and Back

Challenge: Efficiently Reach Large N for Population studies

• High throughput genotyping• High throughput phenotyping• High throughput sample acquisition

DHHS Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS) argues for the health value of a 500,000 to 1M subject study. Estimated cost: $3,000,000,000

Page 20: From Bedside to Bench  and Back

Who?Health Care Utilization

(Hospitalization, ED Visits)+

Genes

Clinical Factors

Page 21: From Bedside to Bench  and Back

NLP (and comedy) is not pretty

HOSPITAL COURSE: ... It was recommended that she receive …We also added Lactinax, oral form of Lactobacillus acidophilus to attempt a repopulation of her gut.

SH: widow,lives alone,2 children,no tob/alcohol.

BRIEF RESUME OF HOSPITAL COURSE: 63 yo woman with COPD, 50 pack-yr tobacco (quit 3 wks ago), spinal stenosis, ...

SOCIAL HISTORY: Negative for tobacco, alcohol, and IV drug abuse.

SOCIAL HISTORY: The patient is a nonsmoker. No alcohol.

SOCIAL HISTORY: The patient is married with four grown daughters,uses tobacco, has wine with dinner.Smoker

Non-Smoker

SOCIAL HISTORY: The patient lives in rehab, married. Unclear smoking historyfrom the admission note…

Past Smoker

Hard to pick

Hard to pick

???

Page 22: From Bedside to Bench  and Back

Crimson: Core Functions

Clinical discardMined PhenotypesMatched

AnonymousID

Richly annotated biospecimens

Page 23: From Bedside to Bench  and Back

Free and Open Source Translational Toolkit: Implementations

DataRepository

(CRC)

FileRepository

IdentityManagement

OntologyManagement

Data Queries DataVisualization

CorrelationAnalysis

De -Identification

Of data

NaturalLanguageProcessing

AnnotatingGenomic

Data

ProjectManagement

WorkflowFramework

Visual TermMapping

Page 24: From Bedside to Bench  and Back

Major Modes (II)